Condition Deep-Dives 11 min read·Updated 22 July 2026 Clinician-reviewed

Nephrogenic Systemic Fibrosis (NSF)

A UK Consultant Nephrologist on nephrogenic systemic fibrosis — a devastating gadolinium-related complication that is now near-eliminated by using group II macrocyclic agents.

  • Clinically Reviewed
  • NHS & NICE Aligned
  • UK Evidence-Based
  • Last Reviewed 22 July 2026

Professor Mohammed Mahdi Althaf

Consultant Nephrologist & Acute Physician

View Credentials

Professor Mohammed Mahdi Althaf

MD, MSc, PgDip (Clin Ed), FRCP, FHEA, FASN

Consultant Nephrologist & Acute Physician · GMC 7216325

View profile →

Direct answer

Triggered by gadolinium MRI contrast in eGFR < 30, AKI or dialysis. Avoid group I linear agents (Omniscan, Magnevist). Use group II macrocyclic (Gadovist, Dotarem) at lowest dose. No effective treatment — prevention only.

Key recommendation: Risk highest with group I linear agents.

Quick answer

✓ Best choices

  • Vegetables, lower-potassium fruit and whole grains
  • Sensible portions of fish, eggs, chicken or tofu
  • Olive oil and unsalted nuts in small amounts

✓ Foods to limit

  • Added salt and ultra-processed foods
  • Phosphate additives in processed meats and ready meals
  • Sugary and energy drinks

Key takeaway

Triggered by gadolinium MRI contrast in eGFR < 30, AKI or dialysis. Avoid group I linear agents (Omniscan, Magnevist). Use group II macrocyclic (Gadovist, Dotarem) at lowest dose. No effective treatment — prevention only.

Who should be cautious

People on dialysis, post-transplant, pregnant or breastfeeding, or taking prescription medication — confirm with your renal team before changes.

Nephrogenic Systemic Fibrosis (NSF)

Pathophysiology & clinical features

Mechanism

  • Free Gd³⁺ released from less-stable chelates in CKD
  • Gd deposits in skin and viscera; recruits CD34⁺ fibrocytes
  • Profibrotic cytokine cascade → systemic fibrosis

PRESENTATION (weeks to months post-GBCA):

  • Burning / pruritus / oedema of distal limbs
  • Skin thickening, hyperpigmentation, peau d'orange
  • Joint contractures (knees, ankles, elbows)
  • Yellow scleral plaques
  • Visceral fibrosis: lung, heart, diaphragm, liver
  • Mobility loss, wheelchair-bound, mortality up to 30%

Diagnosis

  • Clinical + skin biopsy: deep dermal fibrosis, CD34⁺ spindle cells, increased dermal mucin
  • Document GBCA exposure history
  • MHRA Yellow Card mandatory

MHRA agent classification

GROUP I — HIGH RISK (CONTRAINDICATED if eGFR < 30):

  • Gadodiamide (Omniscan)
  • Gadopentetate dimeglumine (Magnevist)
  • Gadoversetamide (OptiMARK)
  • All LINEAR, NONIONIC structure → least stable

GROUP II — LOW RISK (PREFERRED):

  • Gadobutrol (Gadovist)
  • Gadoteridol (ProHance)
  • Gadoterate meglumine (Dotarem, Clariscan)
  • MACROCYCLIC, thermodynamically stable
  • Standard dose: 0.1 mmol/kg

GROUP III — INTERMEDIATE:

  • Gadoxetate (Primovist, hepatic imaging)
  • Gadobenate (MultiHance)
  • Gadofosveset (Ablavar)
  • Linear ionic — better stability than group I

UK Pathway

  • Most NHS trusts have phased out group I agents
  • Default to group II for ALL renal patients
  • Local protocols specify GBCA selection by eGFR

Prevention & management

Pre-mri Checklist

  • Recent eGFR (within 3 months for CKD; same admission for AKI)
  • Confirm dialysis status and last session
  • Indication review — can non-contrast MRI, ultrasound or unenhanced CT answer the clinical question?
  • Informed consent documented

IF eGFR < 30 OR AKI:

  • AVOID GBCA where alternative available
  • If essential: smallest dose of group II macrocyclic agent
  • Single-dose only; no repeat scans within 7 days
  • Document MDT decision

Dialysis Patients

  • Schedule MRI immediately before dialysis session
  • Additional HD at 24 h (3 sessions total) reduces gadolinium burden
  • PD: limited evidence; arrange HD if GBCA essential
  • NO evidence dialysis prevents NSF — risk minimisation only

MANAGEMENT (if NSF develops):

  • Restore kidney function if reversible (e.g. recovery from AKI, transplantation)
  • Skin: physiotherapy, emollients
  • Tried (limited evidence): photopheresis, imatinib, plasmapheresis, sodium thiosulfate
  • MHRA Yellow Card report
  • Specialist dermatology + nephrology MDT
Scleroderma Renal Crisis
Related reading: Scleroderma Renal Crisis.

Key practical tips

Designed for quick scanning — what to order, what to avoid, sensible portions, common mistakes.

  • Cook from scratch when you can
  • Read sodium labels (≤ 0.3 g per 100 g is low)
  • Take any concerns to your GP or renal team early

Clinical guidance

TL;DR summary

Triggered by gadolinium MRI contrast in eGFR < 30, AKI or dialysis. Avoid group I linear agents (Omniscan, Magnevist). Use group II macrocyclic (Gadovist, Dotarem) at lowest dose. No effective treatment — prevention only.

Key takeaways
  • Risk highest with group I linear agents.
  • Group II macrocyclic agents = near-zero risk.
  • Always check eGFR before any GBCA.
  • Dialyse within 2 h post-scan if already on HD.
  • MHRA Yellow Card any suspected case.
Kidney Diet & Nutrition Considerations

Diet is one of the most powerful tools you have to look after your kidneys. UK renal guidance points to a Mediterranean-style, reduced-salt pattern: plenty of vegetables, lower-potassium fruit, whole grains, sensible protein, beans and pulses in moderation, oily fish and olive oil. Personal targets — for potassium, phosphate, protein and fluid — should be set by your renal team based on your bloods.

Foods to prioritise

  • Vegetables, lower-potassium fruit and whole grains
  • Sensible portions of fish, eggs, chicken or tofu
  • Olive oil and unsalted nuts in small amounts

Foods to limit

  • Added salt and ultra-processed foods
  • Phosphate additives in processed meats and ready meals
  • Sugary and energy drinks

Potassium, phosphate and protein needs vary between individuals — please confirm personal targets with your renal team or dietitian. Browse the Kidney Diet Hub for more guides in this cluster.

Frequently asked questions

What is nephrogenic systemic fibrosis?

NSF is a rare but devastating fibrosing disorder of skin, joints and viscera triggered by exposure to gadolinium-based contrast agents (GBCAs) in patients with severe kidney impairment (eGFR < 30, dialysis, or AKI). It presents weeks to months after MRI with skin thickening, peau d'orange induration of limbs, joint contractures, and rarely cardiac, hepatic and pulmonary fibrosis. Mortality up to 30%. No effective treatment — prevention is paramount.

Which gadolinium agents are safest?

MHRA and EMA classify GBCAs into three groups. GROUP I (HIGH risk — contraindicated if eGFR < 30): gadodiamide (Omniscan), gadopentetate (Magnevist), gadoversetamide. GROUP II (LOW risk — preferred): gadobutrol (Gadovist), gadoteridol (ProHance), gadoterate (Dotarem/Clariscan) — these are macrocyclic and thermodynamically stable. GROUP III (intermediate): gadoxetate (Primovist), gadobenate, gadofosveset. UK pathways have largely retired group I agents.

Who is at risk?

eGFR < 30 mL/min/1.73m² (CKD 4–5), dialysis (HD or PD), acute kidney injury of any cause, hepatorenal syndrome, peri-transplant phase. Risk is NEAR ZERO with group II macrocyclic agents at standard dose; nearly all reported NSF cases involved group I linear agents at the time when they were widely used.

How is risk minimised?

Check eGFR before GBCA in all CKD patients. If eGFR < 30 or AKI: AVOID GBCA where possible (use non-contrast MRI, ultrasound, or unenhanced CT). If GBCA essential: use lowest possible dose of a group II agent, single-dose only, and dialyse within 2 h post-scan if already on HD (additional sessions at 24 h reduce gadolinium burden but do not prevent NSF). Document informed consent. MHRA reporting via Yellow Card if any suspected case.

What foods are good for kidney health?

A Mediterranean-style, mostly plant-based, reduced-salt diet is the most consistent evidence-based pattern for kidney health. Build meals around vegetables, lower-potassium fruit, whole grains, fish, eggs or tofu, beans and pulses in moderation, and olive oil.

Nutritional challenges in kidney disease

Many people living with kidney disease have to limit foods because of potassium, phosphate, diabetes, dialysis, appetite changes or simply the time it takes to cook from scratch every day. That can make it harder to keep daily nutrition balanced — particularly for vitamins and minerals that food alone may not fully cover.

Kidney Vitality is a UK-formulated daily nutritional support product designed by Consultant Nephrologist Professor Mohammed Mahdi Althaf with renal nutrition in mind from the start. It keeps doses moderate, leaves out added potassium, phosphate and magnesium, and avoids megadose vitamin A — sitting alongside a kidney-friendly diet, not replacing it.

Why Kidney Vitality fits this need

Built around UK guidance

Aligned with MHRA gadolinium-based contrast advice (2017, updated 2024), Royal College of Radiologists guidance and KDIGO 2024 CKD evaluation.

Designed by a UK Consultant Nephrologist

Formulated and reviewed by Professor Mohammed Mahdi Althaf (GMC 7216325).

Prevention-first & MDT-focused

Practical agent selection, eGFR thresholds and dialysis-timing protocols for radiology and nephrology teams.

Designed by a UK Consultant Nephrologist

Ready to support your kidney health?

If you have been researching kidney health, supplements, CKD nutrition or kidney-friendly living, Kidney Vitality was developed specifically around those principles by Professor Mohammed Mahdi Althaf (GMC 7216325). Nephrologist Developed Daily Multivitamin.

  • No Added Potassium
  • No Added Magnesium
  • No Added Phosphorus
  • No Added Iron
  • One capsule daily
  • UK GMP — BRCGS, NSF GMP, Halal
Subscribe & Save — £20.39/monthCheck your current multivitamin

✓ Free UK tracked delivery  ·  ✓ Delivered every 30 days  ·  ✓ Pause or cancel anytime  ·  ✓ Never run out

ComparisonKidney VitalityTypical high-street multivitamin
Added potassiumNoneOften included
Added phosphateNoneOften included (E338–E452)
Vitamin A (retinol)No megadoseOften high-dose retinol
Kidney-focused formulationYesNo — general population
Consultant Nephrologist involvementYes (GMC 7216325)No
UK GMP manufacturedYes (BRCGS, NSF GMP)Varies

Food supplement. Not a medicine and not a treatment for kidney disease. Speak with your GP, pharmacist or renal team before starting any new supplement, especially in advanced CKD, on dialysis, post-transplant, pregnant or breastfeeding.

Clinical reviewer

Professor Mohammed Mahdi Althaf

Consultant Nephrologist

Acute Physician

GMC 7216325

View Full Biography

Professor Mohammed Mahdi Althaf is a UK Consultant Nephrologist and Acute Physician with a special interest in chronic kidney disease, AKI prevention and renal nutrition. He combines hospital practice with patient education and clinical guidance review.

View professional profile →
View Credentials
  • MD
  • MSc
  • PgDip (Clin Ed)
  • FRCP
  • FHEA
  • FASN

About this article

Written for UK patients and based on:

  • NICE guidance
  • NHS resources
  • British Dietetic Association guidance
  • Kidney Care UK resources
View methodology

Each article is researched against current UK clinical guidance (NICE NG203, NG118, NG136), NHS patient resources, KDIGO and KDOQI international guidelines, and the British Dietetic Association Renal Nutrition Group. Drafts are written by the Kidney Vitality editorial team and reviewed by a UK Consultant Nephrologist before publication. Content is reviewed on a rolling basis and updated when guidance changes.

Editorial standards

  • Clinically reviewed
  • NHS-aligned
  • NICE-aligned
  • Evidence-based
  • Reviewed before publication
View full editorial process

Every article is researched and written by the Kidney Vitality editorial team using current UK clinical guidance (NICE NG203, NG118, NG136), NHS patient resources, KDIGO/KDOQI international guidelines, and British Dietetic Association renal nutrition guidance. Drafts are reviewed for clinical accuracy by Professor Mohammed Mahdi Althaf, MD, MSc, PgDip (Clin Ed), FRCP, FHEA, FASN (Consultant Nephrologist & Acute Physician, GMC 7216325) before publication. Content is updated when UK guidance changes.

References (4)View Sources
  1. NICE NG203: Chronic kidney disease — assessment and management
  2. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
  3. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update
  4. British Dietetic Association — Renal Nutrition Group

Medical disclaimer

This content is educational only and does not replace personalised medical advice.

Read full disclaimer

This page is general information, not personal medical advice. If you have chronic kidney disease, are on dialysis, have had a kidney transplant, are pregnant or breastfeeding, or take prescription medication, please confirm any supplement with your GP, pharmacist or renal team before starting.

← Back to all guides